Hetero is a prominent Indian pharmaceutical company, founded in 1993 by Dr. Ramesh S. Nimmagadda.

Headquartered in Hyderabad, India, it has established itself as a leader in the global generics market. Initially focused on active pharmaceutical ingredients (APIs), Hetero has expanded its operations to encompass finished dosage forms across therapeutic areas, including anti-retrovirals (ARVs), oncology, and cardiovascular drugs. Hetero’s primary offerings include a wide range of generic medicines, as well as specialized formulations.

It is notably recognized for being one of the largest manufacturers of ARVs, supplying to various global organizations. The company operates across over 120 countries, exporting products to markets in North America, Europe, Asia, and Africa. Its global partnerships and alliances bolster its reach, with notable collaborations with major pharmaceutical firms and institutions for research and development.

In terms of market position, Hetero is recognized as one of India’s largest pharmaceutical companies, with strong global sales that contribute significantly to its competitive edge against peers like Cipla, Sun Pharma, and Dr. Reddy’s. Hetero's commitment to quality and affordability has solidified its reputation in both domestic and international markets.

Significant milestones for the company include the launch of its complex generics and biosimilars, enhancing its product portfolio. Recently, Hetero has focused on expanding its footprint in biotechnology and invest in enhancing its research capabilities. As of 2023, Hetero continues to adapt to global healthcare needs and regulatory standards, emphasizing innovation and sustainability in its operations.

Ongoing developments in strategic partnerships and new product launches are key to its vision for future growth